The Korean journal of internal medicine

  • 제29권6호
  • /
  • Pages.713-726
  • /
  • 2014
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Recent advances in treatment of aplastic anemia

  • Shin, Seung Hwan (Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Sung Eun (Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jong Wook (Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 투고 : 2014.09.20
  • 심사 : 2014.09.29
  • 발행 : 2014.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Recent advances in the treatment of aplastic anemia (AA) made most of patients to expect to achieve a long-term survival. Allogeneic stem cell transplantation (SCT) from HLA-matched sibling donor (MSD-SCT) is a preferred first-line treatment option for younger patients with severe or very severe AA, whereas immunosuppressive treatment (IST) is an alternative option for others. Horse anti-thymocyte globuline (ATG) with cyclosporin A (CsA) had been a standard IST regimen with acceptable response rate. Recently, horse ATG had been not available and replaced with rabbit ATG in most countries. Subsequently, recent comparative studies showed that the outcomes of patients who received rabbit ATG/CsA were similar or inferior compared to those who received horse ATG/CsA. Therefore, further studies to improve the outcomes of IST, including additional eltrombopag, are necessary. On the other hand, the upper age limit of patients who are able to receive MSD-SCT as first-line treatment is a current issue because of favorable outcomes of MSD-SCT of older patients using fludarabine-based conditioning. In addition, further studies to improve the outcomes of patients who receive allogeneic SCT from alternative donors are needed. In this review, current issues and the newly emerging trends that may improve their outcomes in near futures will be discussed focusing the management of patients with AA.

키워드

참고문헌

  1. Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol 2013;97:564-572. https://doi.org/10.1007/s12185-013-1331-y
  2. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-3190.
  3. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004;364:355-364. https://doi.org/10.1016/S0140-6736(04)16724-X
  4. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-2519. https://doi.org/10.1182/blood-2006-03-010777
  5. Incidence of aplastic anemia: the relevance of diagnostic criteria: by the International Agranulocytosis and Aplastic Anemia Study. Blood 1987;70:1718-1721.
  6. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study: the French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood 1990;75:1646-1653.
  7. Issaragrisil S. Epidemiology of aplastic anemia in Thailand: Thai Aplastic Anemia Study Group. Int J Hematol 1999;70:137-140.
  8. Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin Med Sci J 1991;6:203-207.
  9. Yong AS, Goh AS, Rahman M, Menon J, Purushothaman V. Epidemiology of aplastic anaemia in the state of Sabah, Malaysia. Med J Malaysia 1998;53:59-62.
  10. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009;147:43-70. https://doi.org/10.1111/j.1365-2141.2009.07842.x
  11. Rozman C, Marin P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet 1987;2:955-957.
  12. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program 2012;2012:292-300.
  13. Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet 1977;2:1145-1148.
  14. Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed) 1981;282:860-863. https://doi.org/10.1136/bmj.282.6267.860
  15. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1983;308:113-118. https://doi.org/10.1056/NEJM198301203080301
  16. Gluckman E, Devergie A, Poros A, Degoulet P. Results of immunosuppression in 170 cases of severe aplastic anaemia: report of the European Group of Bone Marrow Transplant (EGBMT). Br J Haematol 1982;51:541-550. https://doi.org/10.1111/j.1365-2141.1982.tb02817.x
  17. de Planque MM, Bacigalupo A, Wursch A, et al. Longterm follow-up of severe aplastic anaemia patients treated with antithymocyte globulin: Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol 1989;73:121-126. https://doi.org/10.1111/j.1365-2141.1989.tb00230.x
  18. Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 1988;72:1861-1869.
  19. Stryckmans PA, Dumont JP, Velu T, Debusscher L. Cyclosporine in refractory severe aplastic anemia. N Engl J Med 1984;310:655-656. https://doi.org/10.1056/NEJM198403083101013
  20. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine: the German Aplastic Anemia Study Group. N Engl J Med 1991;324:1297-1304. https://doi.org/10.1056/NEJM199105093241901
  21. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-1242. https://doi.org/10.1182/blood-2002-04-1134
  22. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999;93:2191-2195.
  23. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130-1135. https://doi.org/10.1001/jama.289.9.1130
  24. Osugi Y, Yagasaki H, Sako M, et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. Haematologica 2007;92:1687-1690. https://doi.org/10.3324/haematol.11359
  25. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009;144:206-216. https://doi.org/10.1111/j.1365-2141.2008.07450.x
  26. Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001;98:3513-3519. https://doi.org/10.1182/blood.V98.13.3513
  27. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006;107:1308-1314. https://doi.org/10.1182/blood-2005-06-2485
  28. Kim SY, Lee JW, Lee SE, et al. The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis. Genes Chromosomes Cancer 2010;49:844-850.
  29. Saracco P, Quarello P, Iori AP, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008;140:197-205.
  30. Risitano AM. Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. Br J Haematol 2011;152:127-140. https://doi.org/10.1111/j.1365-2141.2010.08439.x
  31. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010;304:1358-1364. https://doi.org/10.1001/jama.2010.1376
  32. Sakaguchi H, Nishio N, Hama A, et al. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia. Haematologica 2014;99:1312-1316. https://doi.org/10.3324/haematol.2013.091165
  33. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430-438. https://doi.org/10.1056/NEJMoa1103975
  34. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 2010;89:851-859. https://doi.org/10.1007/s00277-010-0944-y
  35. Afable MG, 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011;96:1269-1275. https://doi.org/10.3324/haematol.2011.042622
  36. Shin SH, Yoon JH, Yahng SA, et al. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 2013;92:817-824. https://doi.org/10.1007/s00277-013-1674-8
  37. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012;119:5391-5396. https://doi.org/10.1182/blood-2012-02-407684
  38. Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica 2014;99:664-671. https://doi.org/10.3324/haematol.2013.089268
  39. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009;94:348-354. https://doi.org/10.3324/haematol.13829
  40. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006;133:606-611. https://doi.org/10.1111/j.1365-2141.2006.06085.x
  41. Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007;110:1756-1761. https://doi.org/10.1182/blood-2006-11-050526
  42. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011;117:4434-4441. https://doi.org/10.1182/blood-2010-08-304071
  43. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013;98:10-23. https://doi.org/10.1007/s12185-013-1382-0
  44. Geddis AE. Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 2011;57:199-203. https://doi.org/10.1002/pbc.22927
  45. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367:11-19. https://doi.org/10.1056/NEJMoa1200931
  46. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014;123:1818-1825. https://doi.org/10.1182/blood-2013-10-534743
  47. Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008;111:1054-1059.
  48. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy: Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999;107:330-334. https://doi.org/10.1046/j.1365-2141.1999.01693.x
  49. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006;133:622-627. https://doi.org/10.1111/j.1365-2141.2006.06098.x
  50. Scheinberg P, Townsley D, Dumitriu B, et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol 2014;89:467-469. https://doi.org/10.1002/ajh.23669
  51. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010;148:791-796. https://doi.org/10.1111/j.1365-2141.2009.08027.x
  52. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012;119:345-354. https://doi.org/10.1182/blood-2011-05-352328
  53. Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow- up. Blood 2010;115:2136-2141. https://doi.org/10.1182/blood-2009-06-225375
  54. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000;356:1554-1559. https://doi.org/10.1016/S0140-6736(00)03126-3
  55. McCann SR, Bacigalupo A, Gluckman E, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994;13:233-237.
  56. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989;73:606-613.
  57. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: inf luence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992;79:269-275.
  58. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996;87:386-392.
  59. Gale RP, Ho W, Feig S, et al. Prevention of graft rejection following bone marrow transplantation. Blood 1981;57:9-12.
  60. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994;84:941-949.
  61. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007;109:4582-4585. https://doi.org/10.1182/blood-2006-10-052308
  62. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004;103:2490-2497. https://doi.org/10.1182/blood-2003-07-2546
  63. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005;130:747-751. https://doi.org/10.1111/j.1365-2141.2005.05667.x
  64. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLAmatched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007;110:1397-1400. https://doi.org/10.1182/blood-2007-03-081596
  65. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000;96:1690-1697.
  66. Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica 2010;95:2119-2125. https://doi.org/10.3324/haematol.2010.026682
  67. Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using f ludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009;94:1312-1315. https://doi.org/10.3324/haematol.2009.006916
  68. Shin SH, Yoon JH, Yahng SA, et al. Influence of recipient's age on the outcome of HLA-matched sibling transplants in adult patients with severe aplastic anemia who conditioned with f ludarabine-based regimen. Paper presented at: 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta: 1921-1922
  69. Passweg JR, Perez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006;37:641-649. https://doi.org/10.1038/sj.bmt.1705299
  70. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005;36:947-950. https://doi.org/10.1038/sj.bmt.1705165
  71. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica 2010;95:976-982. https://doi.org/10.3324/haematol.2009.018267
  72. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006;108:1485-1491. https://doi.org/10.1182/blood-2006-03-005041
  73. Maury S, Balere-Appert ML, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007;92:589-596. https://doi.org/10.3324/haematol.10899
  74. Viollier R, Socie G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008;41:45-50. https://doi.org/10.1038/sj.bmt.1705894
  75. Kim SY, Lee JW, Lim J, et al. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2007;13:863-870. https://doi.org/10.1016/j.bbmt.2007.03.013
  76. Lee JW, Cho BS, Lee SE, et al. The outcome of unrelated hematopoietic stem cell transplants with total body irradiation (800 cGy) and cyclophosphamide (120 mg/kg) in adult patients with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2011;17:101-108. https://doi.org/10.1016/j.bbmt.2010.06.014
  77. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006;24:5695-5702. https://doi.org/10.1200/JCO.2006.08.0952
  78. Yagasaki H, Kojima S, Yabe H, et al. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graftversus- host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant 2009;15:1603-1608. https://doi.org/10.1016/j.bbmt.2009.08.012
  79. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46:485-501. https://doi.org/10.1038/bmt.2011.11
  80. Lee SE, Yoon JH, Shin SH, et al. In vivo T-cell depletion with low-dose antithymocyte goblulin to reduce acute GVHD in urenlated donor stem cell transplant for patients with severe aplastic anemia. Paper presented at: 18th EHA 2013 Annual Meeting; 2013 Jun 13-16; Stockholm: 380-381.
  81. Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013;119:978-985. https://doi.org/10.1002/cncr.27761
  82. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-3454. https://doi.org/10.1200/JCO.2005.09.117
  83. Wagner JL, Deeg HJ, Seidel K, et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: an update of the Seattle experience. Transplantation 1996;61:54-61. https://doi.org/10.1097/00007890-199601150-00012
  84. Tzeng CH, Chen PM, Fan S, Liu JH, Chiou TJ, Hsieh RK. CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplantation for severe aplastic anemia using HLA-haploidentical family donors. Bone Marrow Transplant 1996;18:273-277.
  85. Xu LP, Liu KY, Liu DH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012;47:1507-1512. https://doi.org/10.1038/bmt.2012.79
  86. Dezern AE, Luznik L, Fuchs EJ, Jones RJ, Brodsky RA. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant 2011;46:1012-1013. https://doi.org/10.1038/bmt.2010.213
  87. Im HJ, Koh KN, Choi ES, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2013;19:754-759. https://doi.org/10.1016/j.bbmt.2013.01.023
  88. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion- dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007;78:487-494. https://doi.org/10.1111/j.1600-0609.2007.00842.x
  89. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;2001:47-61. https://doi.org/10.1182/asheducation-2001.1.47
  90. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008;80:168-176.
  91. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462. https://doi.org/10.1182/blood-2005-08-3430
  92. Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010;116:2448-2454. https://doi.org/10.1182/blood-2010-01-261289
  93. Lee JW, Yoon SS, Shen ZX, et al. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica 2013;98:1045-1048. https://doi.org/10.3324/haematol.2012.077669
  94. Lee SE, Yahng SA, Cho BS, et al. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematol 2013;129:72-77. https://doi.org/10.1159/000342772
  95. Lee JW, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK. Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia. Pediatr Hematol Oncol 2011;28:718-720. https://doi.org/10.3109/08880018.2011.615050
  96. Koh KN, Park M, Kim BE, Im HJ, Seo JJ. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. J Pediatr Hematol Oncol 2010;32:611-614. https://doi.org/10.1097/MPH.0b013e3181e8854d

피인용 문헌

  1. Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study vol.104, pp.4, 2014, https://doi.org/10.1007/s12185-016-2053-8
  2. Comparison of porcine anti‐human lymphocyte globulin and rabbit anti‐human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single‐center study vol.96, pp.3, 2016, https://doi.org/10.1111/ejh.12584
  3. Successful Treatment of Relapsed Acquired Amegakaryocytic Thrombocytopenia with Repeat Cyclosporine vol.90, pp.3, 2014, https://doi.org/10.3904/kjm.2016.90.3.258
  4. Unmanipulated haploidentical haematopoietic stem cell transplantation for children with severe aplastic anaemia vol.174, pp.5, 2016, https://doi.org/10.1111/bjh.14110
  5. Association of Human Leukocyte Antigen DRB1*15 and DRB1*15 : 01 Polymorphisms with Response to Immunosuppressive Therapy in Patients with Aplastic Anemia: A Meta-Analysis vol.11, pp.9, 2014, https://doi.org/10.1371/journal.pone.0162382
  6. Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia vol.51, pp.10, 2014, https://doi.org/10.1038/bmt.2016.140
  7. Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based vol.51, pp.11, 2016, https://doi.org/10.1038/bmt.2016.171
  8. Levamisole suppresses adipogenesis of aplastic anaemia‐derived bone marrow mesenchymal stem cells through ZFP36L1‐PPARGC1B axis vol.22, pp.9, 2014, https://doi.org/10.1111/jcmm.13761
  9. Reactivation and dynamics of cytomegalovirus and Epstein‐Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia vol.103, pp.4, 2014, https://doi.org/10.1111/ejh.13308
  10. The predictive value of pre-treatment paroxysmal nocturnal hemoglobinuria clone on response to immunosuppressive therapy in patients with aplastic anemia: a meta-analysis vol.25, pp.1, 2014, https://doi.org/10.1080/16078454.2020.1848083
  11. Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia vol.55, pp.8, 2014, https://doi.org/10.1038/s41409-020-0820-x
  12. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study vol.192, pp.1, 2021, https://doi.org/10.1111/bjh.17190